Rallybio Corporation
RLYB
$0.66
$0.011.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 674.00K | 761.00K | 848.00K | 636.00K | 598.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 674.00K | 761.00K | 848.00K | 636.00K | 598.00K |
| Cost of Revenue | 14.23M | 14.59M | 14.75M | 19.96M | 28.50M |
| Gross Profit | -13.55M | -13.83M | -13.90M | -19.32M | -27.90M |
| SG&A Expenses | 15.61M | 16.74M | 16.93M | 18.33M | 19.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.93M | 44.16M | 51.23M | 57.83M | 67.30M |
| Operating Income | -38.26M | -43.40M | -50.38M | -57.20M | -66.70M |
| Income Before Tax | -14.17M | -41.65M | -48.19M | -57.78M | -66.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.17 | -41.65 | -48.19 | -57.78 | -66.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.17M | -41.65M | -48.19M | -57.78M | -66.97M |
| EBIT | -38.26M | -43.40M | -50.38M | -57.20M | -66.70M |
| EBITDA | -38.14M | -43.29M | -50.26M | -57.07M | -66.56M |
| EPS Basic | -0.32 | -0.93 | -1.08 | -1.34 | -1.59 |
| Normalized Basic EPS | -0.51 | -0.59 | -0.68 | -0.79 | -0.95 |
| EPS Diluted | -0.32 | -0.93 | -1.08 | -1.34 | -1.59 |
| Normalized Diluted EPS | -0.51 | -0.59 | -0.68 | -0.79 | -0.95 |
| Average Basic Shares Outstanding | 179.33M | 178.87M | 178.16M | 174.16M | 170.13M |
| Average Diluted Shares Outstanding | 179.33M | 178.87M | 178.16M | 174.16M | 170.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |